Clinical Trial Detail

NCT ID	NCT02178722
Title	Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Recruitment	Active, not recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Incyte Corporation
Indications	renal pelvis transitional cell carcinoma salivary gland carcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma lung non-small cell carcinoma peritoneum cancer diffuse large B-cell lymphoma melanoma endometrial adenocarcinoma triple-receptor negative breast cancer clear cell renal cell carcinoma urethra transitional cell carcinoma nasopharynx carcinoma Her2-receptor negative breast cancer fallopian tube carcinoma prostate transitional cell carcinoma hepatocellular carcinoma endometrial transitional cell carcinoma bladder urothelial carcinoma stomach cancer ovary epithelial cancer fallopian tube transitional cell carcinoma ureter transitional cell carcinoma colorectal cancer renal cell carcinoma ovary transitional cell carcinoma
Therapies	Epacadostat + Pembrolizumab
Age Groups:	adult senior